Dose Finding Study of Thymoglobulin (ATG) in Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGVHD).

Trial Profile

Dose Finding Study of Thymoglobulin (ATG) in Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGVHD).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2012 Actual patient number is 1 according to ClinicalTrials.gov.
    • 20 Jan 2012 Planned end date Aug 2007 added as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top